Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study  by Crijns, Harry J.G.M. et al.
International Journal of Cardiology 172 (2014) 588–594
Contents lists available at ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdContemporary real life cardioversion of atrial ﬁbrillation: Results from
the multinational RHYTHM-AF study☆Harry J.G.M. Crijns a,⁎, Bob Weijs a, Anna-Meagan Fairley a, Thorsten Lewalter b, Aldo P. Maggioni c,
Alfonso Martín d, Piotr Ponikowski e, Mårten Rosenqvist f, Prashanthan Sanders g, Mauricio Scanavacca h,
Lori D. Bash i, François Chazelle j, Alexandra Bernhardt k, Anselm K. Gitt k,
Gregory Y.H. Lip l, Jean-Yves Le Heuzey m
a Department of Cardiology and Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, The Netherlands
b University of Bonn, Bonn, Germany
c ANMCO Research Center, Florence Italy
d University Hospital Severo Ochoa, Madrid, Spain
e Medical University, Wroclaw, Poland
f Karolinska Institutet, Stockholm, Sweden
g Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia
h University of São Paulo, São Paulo, Brazil
i Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA
j MSD France, Paris, France
k Institut für Herzinfarktforschung, Ludwigshafen, Germany
l University of Birmingham Centre for Cardiovascular Sciences, Department of Cardiology, City Hospital, Birmingham, United Kingdom
m Hôpital Européen Georges Pompidou, René Descartes University, Paris, France☆ All authors take responsibility for all aspects of the reli
the data presented and their discussed interpretation.
⁎ Corresponding author at: Department of Cardiology
Center, P Debyelaan 25, P.O. Box 5800, 6202 AZ Maastric
433875093; fax: +31 433875104.
E-mail address: hjgm.crijns@mumc.nl (H.J.G.M. Crijns
0167-5273/$ – see front matter © 2014 Elsevier Ireland L
http://dx.doi.org/10.1016/j.ijcard.2014.01.099a b s t r a c ta r t i c l e i n f oArticle history:
Received 10 July 2013
Received in revised form 12 December 2013
Accepted 19 January 2014
Available online 25 January 2014
Keywords:
Atrial ﬁbrillation
Cardioversion
Rhythm control
Stroke
Aims: Electrical and pharmacological cardioversion (ECV, PCV) are important treatment options for symptomatic
patients with recent onset atrial ﬁbrillation (AF). RHYTHM-AF is an international registry of present-day cardio-
version providing information that is not currently available on country differences and acute and long-term ar-
rhythmia outcomes of ECV and PCV.
Methods and results: 3940 patients were enrolled, of whom 75% underwent CV. All patients were followed for
2 months. There were large variations concerning mode of CV used, ECV being heterogeneous. A choice of PCV
drug depended on the clinical patient proﬁle. Sinus rhythm was restored in 89.7% of patients by ECV and in
69.1% after PCV. Among patients not undergoing CV during admission, 34% spontaneously converted to sinus
rhythmwithin 24 h. ECV wasmost successful in patients pretreated with antiarrhythmic drugs (mostly amioda-
rone). PCV was enhanced by class Ic antiarrhythmic drugs; conversion rate on amiodarone was similar to that
seen with rate control drugs. Female patients and those with paroxysmal and ﬁrst detected AF as well as those
without previous ECV responded well to PCV. The median duration of hospital stay was 16.2 and 24.0 h for
ECV and PCV patients, respectively. There were very few CV-related complications regardless of mode of CV.
Chronic maintenance of sinus rhythm was enhanced in patients on chronic antiarrhythmic drugs, beta-
blockers or inhibitors of the renin–angiotensin system.
Conclusions:Mode of CV varied signiﬁcantly, but both PCV and ECV were safe and effective. Class Ic drugs were
most effective conversion drugs, but amiodarone is used most frequently despite providing merely rate control
rather than shorten time to conversion.© 2014 Elsevier Ireland Ltd. All rights reserved.ability and freedom from bias of
, Maastricht University Medical
ht, The Netherlands. Tel.: +31
).
td. All rights reserved.1. Introduction
Atrial ﬁbrillation (AF) is common and often accompanied by inca-
pacitating symptoms [1]. The management of newly detected atrial ﬁ-
brillation (AF) relies on appropriate antithrombotic management,
detection and treatment of associated cardiovascular diseases, and
symptom alleviation [2]. Since cardiovascular outcomes are similar in
AF patients receiving both rate and rhythm control therapies, rate
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adequate symptom relief, restoration of sinus rhythm becomes the
eventual target.
Cardioversion (CV) of AF is critical in alleviating symptoms acutely.
Both pharmacological (PCV) [5,6] and electrical cardioversion (ECV) [7]
are widely accepted. PCV (including the “pill-in-the-pocket-approach”)
is frequently performed in patients with recurrent paroxysmal AF, but
caution is needed to avoid complications, such as acute heart failure, bra-
dycardia, and ventricular arrhythmias [5,8–10]. ECV ismore effective than
PCV, especially in persistent AF, but often requires hospitalization,Table 1a
Baseline characteristics by mode of cardioversion.
TOTAL
(n = 3940)
All CV
(n = 2972)
ECV
(n = 1946)
PC
(n
Demographics
Number of patients (%) 3940 2972 (75) 1946 (49) 10
Age (years) 66 ± 12 66 ± 12.2 67 ± 11 66
Female sex, n (%) 1479 (37.6) 1108 (37,3) 633 (32.5) 47
BMI (kg/m2) 28.4 ± 61 28.3 ± 5.5 28.6 ± 5.8 27
Heart Rate (beats per minute) 106 ± 31 105 ± 31 95 ± 27 12
Site of admission
Emergency department 33.0% 34.6% 15.9% 70
Cardiology ward 46.1% 45.0% 59.2% 17
Intensive care unit 5.1% 4.8% 4.3% 5.9
Other 15.8% 15.5% 20.6% 6.0
Comorbidity
Hypertension, n (%) 62.4% 62.2% 62.5% 61
Systolic blood pressure (mmHg) 131.6 ± 20.3 131.7 ± 20.4 131.1 ± 19.0 13
Diastolic pressure (mmHg) 80.0 ± 13.3 80.2 ± 13.7 80.2 ± 12.9 80
Coronary artery disease, n (%) 893 (22.7) 663 (22.3) 457 (23.5) 20
Valvular heart disease, n (%) 539 (13.7) 395 (13.3) 285 (14.6) 11
Diabetes mellitus, n (%) 679 (17.3) 485 (16.3) 323 (16.6) 16
HF NYHA I-II 11.3% 11.3% 13.1% 8.1
HF NYHA III-IV 3.7% 3.5% 4.0% 2.4
Chronic obstructive pulmonary disease 7.8% 7.7% 5.8% 11
Thromboembolism, n (%) 239 (6.1) 180 (6.1) 126 (6.5) 54
History of Stroke 2.9% 2.8% 3.0% 2.5
History of TIA 2.5% 2.5% 2.6% 2.4
Peripheral vascular disease 6.3% 6.2% 5.6% 7.1
Hemorrhagic complication, n (%) 47 (1.2) 32 (1.1) 20 (1.1) 12
Hyperthyroidism 4.3% 4.6% 5.3% 3.3
CHA2DS2-VASc N1 69.7% 69.1% 69.3% 68
AF characteristics
1st detected AF 32.1% 31.3% 23.1% 46
Paroxysmal AF 29.4% 28.8% 21.7% 42
Persistent AF 31.2% 33.0% 45.5% 9.2
Total AF history (years) 4.5 ± 5.5 4.6 ± 5.5 4.4 ± 5.5 5.0
Current episode b48 h, n (%) 1575 (50.7) 1235 (50.6) 419 (27.0) 81
Previous Cardioversion 33.2% 35.1% 38.6% 28
Previous ECV 45.2% 47.3% 55.8% 22
Previous PCV 28.5% 28.5% 15.7% 64
Currently symptomatic, n (%) 3338 (85.0) 2526 (85.0) 1574 (80.9) 95
Echocardiography (n= 2024)
TTE/TEE performed 51.6/24.1% 48.6/23.9% 51.5/33.6% 43
Left atrial diameter (mm) 44.2 ± 7.4 44.5 ± 7.5 45.6 ± 7.1 42
Left atrial diameter N 40 mm 55% 55% 60% 43
LVEF b40% 19.7% 20.5% 22.7% 15
Medication at inclusion (n= 3926)
Vitamin K antagonist, n (%) 2206 (56.1) 1744 (58.7) 1514 (77.8) 23
Heparin, n (%) 340 (8.6) 221 (7.4) 144 (7.4) 77
No antithrombotic treatment, n (%) 796 (20.3) 583 (19.6) 1541 (7.9) 42
ACE-inhibitor/ARB, n (%) 2171 (55.1) 1641 (55.2) 1157 (59.5) 48
Beta-blocker, n (%) 1648 (42) 1247 (42.0) 1008 (51.9) 23
Digoxin or digitoxin 9.0% 8.9% 12.0% 3.0
Verapamil or diltiazem 3.3% 3.3% 3.8% 2.2
Flecainide or propafenone 8.0% 8.1% 6.6% 10
Sotalol 3.6% 3.8% 4.3% 2.8
Amiodarone 16.8% 16.9% 22.5% 6.2
Dronedarone 2.7% 2.7% 3.8% 0.8anesthesiology support and greater recovery time [11]. Both are generally
safe and effective in producing sinus rhythm acutely [9].
Recommendations, treatments, and goals of rhythm control are
clearly given in the guidelines; [2] however, contemporary observation-
al data on cardioversion practices are scarce [9,12–14]. The RHYTHM-AF
study described clinical routines and outcomes of CV in patientswith AF
considered for rhythm control [15]. The present paper describes the
main study results, focusing on patient characteristics, treatment pat-
terns, and outcomes related to CV from a prospectively collected inter-
national multicenter registry.V
= 1026)
No CV
(n = 968)
P-value
(ALL CV/no CV)
P-value
(ECV/no CV)
P-value
(PCV/no CV)
P-value
ECV/PCV
26 (26) 968 (25)
± 14.2 67 ± 12 0.35 0.26 0.73 0.73
5 (46.3) 371 (38.4) 0.70 0.02 b0.01 b0.01
.8 ± 4.9 28.7 ± 7.7 0.73 0.14 0.21 0.06
6 ± 28 108 ± 31 0.09 b0.001 b0.001 b0.001
.1% 28.1% b0.01 b0.001 b0.001 b0.001
.9% 49.6% 0.09 b0.001 b0.001 b0.001
% 5.7% 0.41 0.15 0.89 0.09
% 16.5% 0.62 0.02 b0.001 b0.001
.7% 62.8% 0.85 0.92 0.75 0.79
2.9 ± 22.7 131.5 ± 19.8 0.83 0.92 0.35 0.18
.1 ± 15.0 79.5 ± 12.0 0.12 0.09 0.46 0.72
6 (20.1) 230 (23.8) 0.48 0.92 0.09 0.09
0 (10.7) 144 (14.9) 0.31 0.92 0.02 0.02
2 (15.8) 194 (20.3) 0.02 0.09 0.02 0.73
% 11.1% 0.89 0.19 0.09 b0.001
% 4.4% 0.25 0.73 0.09 0.09
.2% 8.2% 0.75 0.09 0.09 b0.001
(5.3) 59 (6.1) 0.98 0.81 0.56 0.29
% 3.1% 0.79 0.94 0.55 0.55
% 2.3% 0.84 0.78 0.98 0.79
% 6.7% 0.73 0.39 0.81 0.18
(1.2) 15 (1.6) 0.35 0.34 0.60 0.86
% 3.2% 0.12 0.09 0.94 0.09
.0% 71.4% 0.30 0.52 0.18 0.48
.8% 34.6% 0.09 b0.001 b0.001 b0.001
.4% 31.2% 0.25 b0.001 b0.001 b0.001
% 25.5% b0.001 b0.001 b0.001 b0.001
± 5.5 4.5 ± 5.2 0.75 0.99 0.24 0.11
6 (91.6) 340 (51.4) 0.81 b0.001 b0.001 b0.001
.5% 27.4% b0.001 b0.001 0.73 b0.001
.4% 37.9% b0.01 b0.001 b0.001 b0.001
.3% 28.7% 0.96 b0.001 b0.001 b0.001
2 (92.8) 812 (84.8) 0.94 0.02 b0.001 b0.001
.1/5.6% 60.7/24.7% b0.001/0.75 b0.001 b0.001 b0.001
.0 ± 7.7 43.6 ± 7.2 0.09 b0.001 0.02 b0.001
.4% 55.3% 0.90 0.15 b0.01 b0.001
.5% 18% 0.31 0.09 0.42 0.02
0 (22.4) 462 (48.3) b0.001 b0.001 b0.001 b0.001
(7.5) 118 (12.2) 0.001 b0.001 b0.01 0.94
9 (41.8) 213 (22.3) 0.12 b0.001 b0.001 b0.001
4 (47.2) 530 (54.8) 0.89 0.09 b0.01 b0.001
9 (23.3) 401 (42.0) 1.00 b0.001 b0.001 b0.001
% 9.2% 0.86 0.09 b0.001 b0.001
% 3.4% 0.90 0.73 0.18 0.09
.8% 8.0% 0.94 0.29 0.09 b0.001
% 2.9% 0.33 0.14 0.94 0.09
% 16.6% 0.92 b0.01 b0.001 b0.001
2.5% 0.83 0.14 0.02 b0.001
Table 1b
Baseline characteristics by class of cardioversion drug.
PCV Class Ic
(n = 306)
PCV Class III⁎)
(n = 489)
PCV Other drugs#)
(n = 231)
P-value
(Ic/III)
P-value
(Ic/other)
P-value
(III/other)
Demographics
Number of patients (%) 306 (8) 489 (12) 231 (6)
Age (years) 61 ± 14 70 ± 13 65 ± 15 b0.001 0.04 b0.01
Female sex, n (%) 130 (42.5) 241 (49.3) 104 (45.0) 0.13 0.71 0.43
BMI (kg/m2) 27.4 ± 4.7 28.2 ± 5.0 27.8 ± 5.1 0.11 0.41 0.62
Heart rate (beats per minute) 125 ± 26 125 ± 28 130 ± 27 0.85 0.11 0.11
Site of admission
Emergency department 81.4% 61.3% 73.6% b0.001 0.11 0.04
Cardiology ward 14.7% 19.6% 18.6% 0.16 0.36 0.84
Intensive care unit 0.7% 11.7% 0.9% b0.001 0.84 b0.001
Other 3.3% 7.4% 6.9% 0.11 0.11 0.87
Comorbidity
Hypertension, n (%) 50.0% 69.9% 59.7% b0.001 0.11 0.04
Systolic blood pressure (mmHg) 134.3 ± 21.3 131.9 ± 23.0 133.1 ± 23.6 0.31 0.59 0.82
Diastolic pressure (mmHg) 82.0 ± 14.0 78.3 ± 15.4 81.5 ± 15.0 0.04 0.78 0.11
Coronary artery disease, n (%) 27 (8.8) 137 (28.0) 42 (18.2) b0.001 0.04 0.04
Valvular heart disease, n (%) 12 (3.9) 70 (14.3) 28 (12.1) b0.001 b0.01 0.58
Diabetes mellitus, n (%) 34 (11.1) 90 (18.4) 38 (16.5) 0.04 0.14 0.69
HF NYHA I-II 4.6% 9.2% 10.4% 0.11 0.04 0.77
HF NYHA III-IV 0.3% 4.3% 1.3% b0.01 0.30 0.11
Chronic obstructive pulmonary disease 8.2% 12.9% 11.7% 0.11 0.29 0.78
Thromboembolism, n (%) 7 (2.3) 28 (5.7) 19 (8.2) 0.11 0.04 0.34
History of stroke 1.3% 2.9% 3.1% 0.26 0.27 0.91
History of TIA 1.0% 2.3% 4.4% 0.31 0.11 0.22
Peripheral vascular disease 4.3% 9.4% 6.2% 0.04 0.47 0.26
Hemorrhagic complication, n (%) 4 (1.3) 6 (1.2) 2 (0.9) 0.92 0.77 0.78
Hyperthyroidism 2.7% 3.5% 3.7% 0.71 0.71 0.91
CHA2DS2-VASc N1 50.7% 79.3% 56.4% b0.001 b0.01 b0.001
AF characteristics
1st detected AF 35.9% 53.6% 46.8% b0.001 0.11 0.17
Paroxysmal AF 54.6% 34.4% 43.3% b0.001 0.04 0.11
Persistent AF 8.8% 9.4% 9.1% 0.84 0.92 0.91
Total AF history (years) 5.8 ± 5.7 4.3 ± 5.4 4.6 ± 5.1 0.04 0.11 0.47
Current episode b48 h, n (%) 280 (94.9) 348 (89.7) 188 (90.4) 0.11 0.11 0.84
Previous Cardioversion 38.2% 23.1% 26.8% b0.001 0.04 0.42
Previous ECV 23.9% 22.0% 20.2% 0.81 0.68 0.84
Previous PCV 68.5% 59.2% 66.2% 0.19 0.83 0.44
Currently symptomatic, n (%) 299 (97.7) 437 (89.4) 216 (93.5) b0.001 0.11 0.14
Echocardiography (n= 2024)
TTE/TEE performed 28.8/3.3% 56.2/6.3% 34.2/6.9% b0.001/0.13 0.30/0.11 b0.001/0.84
Left atrial diameter (mm) 40.8 ± 7.0 42.2 ± 7.2 42.5 ± 9.9 0.17 0.47 0.77
Left atrial diameter N 40 mm 37% 46% 41% 0.25 0.77 0.55
LVEF b40% 1.1% 19% 19.7% b0.001 b0.001 0.91
Medication at inclusion (n= 3926)
Vitamin K antagonist, n (%) 64 (20.9) 114 (23.3) 52 (22.5) 0.59 0.78 0.86
Heparin, n (%) 11 (3.5) 49 (10.0) 18 (7.8) b0.01 0.11 0.39
No antithrombotic treatment, n (%) 148 (48.4) 180 (36.8) 101 (43.7) 0.04 0.43 0.16
ACE-inhibitor/ARB, n (%) 114 (37.3) 265 (54.2) 105 (45.5) b0.001 0.13 0.11
Beta-blocker, n (%) 79 (25.8) 117 (23.9) 43 (18.6) 0.71 0.11 0.20
Digoxin or digitoxin 1.0% 4.3% 3.0% 0.04 0.16 0.57
Verapamil or diltiazem 2.0% 2.2% 2.6% 0.84 0.77 0.84
Flecainide or propafenone 21.2% 4.9% 9.5% b0.001 b0.01 0.11
Sotalol 5.2% 1.4% 2.6% 0.04 0.23 0.41
Amiodarone 2.3% 9.4% 4.8% b0.001 0.20 0.11
Dronedarone 1.0% 0.6% 0.9% 0.71 0.91 0.81
⁎) Class III drugs included amiodarone, in all but 7 cases of other class III drugs. #) Other abbreviations: ACE-I: angiotensin-converting-enzyme inhibitor, ARB: angiotensin II receptor
blockers, AF: atrial ﬁbrillation, TTE: transthoracic echocardiogram, TEE: transesophageal echocardiogram.
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2.1. Design and study population
The design of the study has been reported in detail previously [15]. Brieﬂy, RHYTHM-
AF is a prospective international multicenter observational study ﬁelded in 10 countries:
Australia, Brazil, France, Germany, Italy, Netherlands, Poland, Spain, Sweden and the
United Kingdom. A total of 3940 consecutive patients with recent onset AF considered
for CV were enrolled from participating hospitals and acute care centers between May
2010 and June 2011. All patients at least 18 years old with documented AF as conﬁrmed
by electrocardiogram and in whom a CV was one of the planned therapeutic optionswere considered for the study. Only patients who were already enrolled in the
current trial, otherwise enrolled in a separate trial, and patients with atrial ﬂutter were
excluded.
The protocol did not recommend or discourage any treatments, procedures, or exam-
inations that were not part of routine care. As a result, the eventual decision to perform
cardioversion –whether pharmacological or electrical –was left at the discretion of the at-
tending physician. Informed consent was obtained from all patients and the study was
conducted in accordance with principles of Good Clinical Practice and was approved by
the appropriate institutional review boards and regulatory agencies. All data were collect-
ed electronically in a central database and follow-up data were collected 60 days after
enrollment.
Fig. 1.Modes of cardioversion and procedural characteristics. CV: cardioversion; PCV: pharmacological cardioversion; ECV: electrical cardioversion; TEE: transesophageal echocardiography;
AAD: antiarrhythmic drug; IV: intravenous; PM: pacemaker.
Fig. 2. Use of anti-thrombotic drugs at enrollment. Percentages add up to N 100% because
some patients used combinations of antithrombotic drugs. APD: antiplatelet drug; ATT:
antithrombotic treatment; ECV: electrical cardioversion; PCV: pharmacological cardiover-
sion; VKA: vitamin K agonist.
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2.2. Endpoints
PCV was considered successful if sinus rhythm or atrial rhythm was obtained within
24 hours after its initiation. Time to sinus rhythmwas noted separately. ECV was deﬁned
as successful if sinus rhythmwas obtained andmaintained for at least 10 minutes after the
last shock. We grouped conversion drugs into Vaughan-Williams [16] Class Ic (ﬂecainide,
propafenone), and Class III drugs (almost exclusively amiodarone, and sotalol in only 2 in-
stances). Other drugs used for conversion as reported by physicians included almost ex-
clusively the typical rate control drugs (i.e., digitalis, beta-blockers, and verapamil or
diltiazem). No prespeciﬁed guidelines were provided in terms of anticoagulation.
2.3. Statistical analysis
Baseline variableswere compared bymode of cardioversion, aswell as by class of drug
used for PCV using χ2 tests (categorical variables) and Kruskal–Wallis tests (continuous
variables). Multivariable logistic regression was performed to detect (a) factors indepen-
dently associated with success of ECV and PCV, as well as determinants of successful
PCV on class Ic and class III antiarrhythmic drugs (AAD); and to detect (b) determinants
of maintenance of sinus rhythm at 2 months in all patients discharged in sinus rhythm.
Variableswere included in the logistic regression for biological relevance and if shown sig-
niﬁcant (p b 0.1) in univariate analysis. Corrections for multiple comparisons were made
according to Benjamini and Hochberg [17]. All statistical analyses were performed with
SAS statistical software (SAS Institute, release 9.2, Cary, NC, USA), and statistical signiﬁ-
cance was assumed for P b 0.05.
3. Results
3.1. Patient characteristics
Tables 1a and 1b shows patient characteristics by mode of treat-
ment. Patients undergoing ECVor noCV at all weremore often admitted
in cardiology wards; those receiving PCV were mostly treated in the
emergency department. Hypertension, coronary artery disease and dia-
beteswere themost prevalent associated comorbidities. Patients under-
going class Ic-PCV had the most favorable clinical proﬁle. Persistent AF
was themost frequent type of AF among ECV patients, whereas PCV pa-
tients predominantly had either ﬁrst-detected or paroxysmal AF, nearly
all presenting very early after AF onset.
At enrollment, one-third of patients had a breakthrough arrhythmia,
i.e. they were using prophylactic class Ic (8%) or class III AADs (23%).
Among those who did not undergo CV, reasons for avoiding the inter-
vention were spontaneous sinus rhythm, planned CV after discharge,spontaneous echo-contrast or left atrial thrombus on transesophageal
echocardiography (TEE), or uncertain duration of current AF episode
duration (Fig. 1). Palpitations were reported by 72% of PCV patients
and only by 40% of ECV patients; in contrast shortness of breath was
more frequent in ECV patients (44% vs. 29%). Standard echocardiogra-
phy was performed most frequently in patients not receiving CV
(61%) and least frequently in class Ic drug PCV patients (29%). Pre-
procedural TEE was done mostly in patients undergoing ECV.
3.2. Cardioversion characteristics and outcomes
Overall, CV was performed a median of 4.0 (IQR 1.4–25.5) hours
after admission, i.e. after 6 (2.4–40) hours for ECV and 1.7 (0.6–8.7)
hours for PCV. Among patients undergoing class Ic PCV and class III
PCV, treatment was administered at 1.1 (IQR 0.34–2.3) and 1.5 (IQR
0.37–25) hours, respectively. Use of antithrombotic treatment is sum-
marized in Fig. 2.
Overall, CV was successful in 82.6% of the patients (ECV 89.7%, PCV
69.1%). Class Ic and class III PCV (amiodarone) was successful in 77%
and 68% of cases, whereas 57% of patients treated by non-
antiarrhythmic drugs converted to sinus rhythm. Class Ic drugs acceler-
ated conversion to sinus rhythm as compared to amiodarone and the
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72% and 63% of patients, respectively. Patients undergoing cardiover-
sion using intravenous amiodarone converted more readily to sinus
rhythm when already on oral amiodarone (n = 32) compared to
those without chronic oral amiodarone (n = 404): by 2 hours almost
40% versus only 20%, respectively.
The increase in the use of class III drugs after cardioversion was sig-
niﬁcant, mainly due to change in amiodarone prescriptions. Far fewer
patients were managed long term with class Ic drugs. The rise in class
III and Ic drug prescription after conversion was especially apparent in
patients undergoing class III (amiodarone) and class Ic drug conversion,
respectively (Fig. 4).
Themedian duration of hospital staywas 16.2 (IQR 5.2–69) and 24.0
h (IQR 7.6–87.3) for ECV and PCV patients, respectively. It was longer in
patients undergoing Class III PCV (57.5 h [range: 15.3–162.3]) compared
to Class Ic PCV (8.4 h [range: 4.4–22.6]). The duration of hospitalization
was longer in patients with unsuccessful compared to successful CV:
22.8 vs. 15.8 for ECV and 34.5 vs. 20.0 h for PCV, respectively.
There were few complications experienced during the ﬁrst 5 days
after admission, regardless of CV strata (Table 2). Two months after ad-
mission, 64.3% of patients were in sinus rhythm. Factors independently
associatedwith successful ECV or PCV andmaintenance of sinus rhythm
at 2 months follow-up, after multivariate adjustment, are presented in
Table 3.Fig. 3. Time to conversion on intraven4. Discussion
RHYTHM-AF provides new comprehensive data on clinical cardiover-
sion of AF. Herein we show that CV modality applied depends on type
and duration of AF, cardioversion history, and patient symptoms. Class
Ic drugs are most effective but their use is relatively limited to healthier
patients. Of note, amiodarone does not perform better for PCV than the
typical rate control drugs in accelerating conversion, but is usedmost fre-
quently, especially in patients inwhom class Ic drugs are contraindicated.
We observed PCV to shorten time to conversion and if successful, also re-
duce time spent in the hospital after cardioversion. Early cardiovascular
complications related to CV appear infrequent.
Amiodarone pretreatment and the presence of an anesthesiologist
were associated with successful ECV. Pretreatment with amiodarone,
but also with ﬂecainide, ibutilide, propafenone, or sotalol may enhance
success of ECV. [2,18] In RHYTHM-AF, amiodarone was used most fre-
quently, likely due to the fact that pretreatment with other agents
may be unsafe, while rational application of amiodarone always in-
cludes pretreatment for its remarkable pharmacokinetics. The presence
of an anesthesiologist during ECV also appeared to enhance cardiover-
sion. This may relate to deeper sedation with less adrenergic activation
upon awakening, use of less arrhythmogenic sedation, or to increased
focus of the healthcare provider on the cardioversion itself with more
aggressive application of repeated shocks as needed. In light of theseous and oral AAD by type of drug.
Table 2
Distribution of complications over time after ECV, PCV or no CV.
Complications ECV PCV no CV Total
n = 1946 n = 1026 n = 968 n = 3940
Death
≤5 days 1 (0.05%) 1 (0.10%) 1 (0.10%) 3 (0.08%)
N5 days ≤ 70 days 6 (0.31%) 7 (0.68%) 9 (0.93%) 22 (0.56%)
N70 days _ 1 (0.10%) 2 (0.21%) 3 (0.08%)
Thromboembolic event
≤5 days _ _ _ _
N5 days ≤ 70 days 5 (0.26%) 4 (0.39%) 2 (0.21%) 11 (0.28%)
N70 days 4 (0.21%) _ _ 4 (0.10%)
Heart failure
≤5 days 1 (0.05%) 1 (0.10%) _ 2 (0.05%)
N5 days ≤ 70 days 8 (0.41%) 4 (0.39%) 4 (0.41%) 16 (0.41%)
N70 days 1 (0.05%) _ _ 1 (0.03%)
Major bleeding
≤5 days _ _ _ _
N5 days ≤ 70 days _ 2 (0.19%) 3 (0.31%) 5 (0.13%)
N70 days 1 (0.05%) _ _ 1 (0.03%)
Bradycardia/hypotension
≤5 days _ _ _ _
N5 days ≤ 70 days 9 (0.46%) 4 (0.39%) 5 (0.52%) 18 (0.46%)
N70 days 3 (0.15%) 1 (0.10%) _ 4 (0.10%)
Bradycardia was deﬁned as requiring temporary or permanent artiﬁcial pacing.
Fig. 4. Change of antiarrhythmic treatment after inclusion: comparison of the distribution
of antiarrhythmic drugs used at admission and discharge in all patients aswell as per type
of cardioversion.
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may consider revising local procedure, type of sedation, engaging anes-
thesiologist assistance, or amiodarone pretreatment.
PCV shortens time to conversion (Fig. 3), thereby effectively limiting
symptoms and reducing time spent in the hospital. Especially class Ic
drugs accelerated conversion to sinus rhythm and were associated
with a signiﬁcantly higher conversion rate within 24 hours compared
to amiodarone and the rate control drugs. Conversion to sinus rhythm
was independently associated with gender, type of AF, and history of
ECV. It is uncertain why women responded better to PCV, although
pharmacokinetic differences may have played a role as dose adjust-
ments are rarely performed in clinical practice. It iswell known that par-
oxysmal AF patients respondmuchbetter to PCV than persistent AF; the
same may hold for ﬁrst-detected AF, which may include a signiﬁcant
number of self-terminating AF. Prior ECV appeared to be associated
with a reduced conversion rate of PCV. Apparently, a previous ECV
may indicate more resistant AF precluding successful conversion
when PCV is chosen.
Drug choice for PCV depended on patient characteristics, with amio-
darone mainly used in patients with higher disease burden. Indeed, a
relatively high prevalence of CHA2DS2-VASc score N1 among amioda-
rone PCVs was observed, compared to all other PCVs. Speciﬁcally the
prevalence of heart failure, coronary artery disease and valvular heart
disease was relatively high in amiodarone PCVs. A similar disease bur-
denwas seen among no CV patients, a potential reason for deferring CV.
In patients with structural heart disease, amiodarone is one of the
recommended conversion drugs [2]; however, in absence of structural
heart disease, class Ic drugs are preferred since cardioversion with ami-
odarone occurs many hours later than with ﬂecainide or propafenone
[19] (Fig. 3). Despite recommendations, amiodarone and even typical
rate control drugs were used in many patients, which may have led to
avoidable CV failure, the need for back-up ECVs, and prolonged hospi-
talization. Of note, amiodarone performed similarly to rate control
drugs, rendering its application for shortening conversion time futile.
On the other hand, amiodarone provides acute rate control, which is
crucial in the wait-and-see approach to CV. It is noteworthy that there
was little difference between oral and intravenous amiodarone
concerning conversion rates, whichmakes it hard to justify intravenous
amiodarone in clinical practice with its hazards like hypotension or
thrombophlebitis.
Oral propafenone appeared less effective in producing sinus rhythm
than ﬂecainide, perhaps due to the relatively low dose of oral
propafenone used. Whereas ﬂecainide was applied as recommended,
[2,5] propafenone was underdosed (median dose 300 mg). Althoughnot very likely, propafenone underdosingmight relate to recent clinical
experience that the drug can produce signiﬁcant adverse effects [10].
Before enrollment, two thirds of patients had one or more previous
AF episodes, of which only one third had a breakthrough arrhythmia,
which is consistent with previous research. [9] This suggests that most
patients do not use an antiarrhythmic drug to prevent new attacks be-
tween episodes, presumably because of a low attack rate, experiencing
theﬁrst ever cardioversion (two-thirds of included patients), or because
of the risks of chronic antiarrhythmic drug prophylaxis. Finally patient's
preference may have played a role in not starting antiarrhythmic drug
prophylaxis after previous attack(s). Although breakthrough AF may
be considered more severe to treat, add-on class Ic drug treatment
was similarly effective compared to class Ic conversion in drug-free
patients. Patients on chronic drug treatment with breakthrough AF fre-
quently add onﬂecainide or propafenone at home, although, pill-in-the-
pocket propafenone has been reported to be associated with adverse
events [10]. Nevertheless, many patients with breakthrough AF fare
well with such a strategy, thus avoiding hospitalizations.
Patients using AAD both at admission and discharge maintained
sinus rhythm in the short term (2 months) signiﬁcantly better than
those who were put on these agents only at discharge or who were
kept off AAD. In line with recent studies, [20,21] the registry supports
the notion that pretreatment and continued antiarrhythmic drug pro-
phylaxis is more effective than other antiarrhythmic drug strategies or
no prophylaxis. Additionally, we observed that beta-blockers and inhib-
itors of the renin–angiotensin system reduced short-term recurrences.
Several previous studies have shown that in the presence of amioda-
rone, angiotensin receptor blockers (ARB) and ACE-inhibitors (ACE-i)
help to prevent recurrences after cardioversion. [2] In the present
study, the effect of ACE-i/ARB was independent of continued antiar-
rhythmic drug use. This may relate to the relatively short-term follow-
up of 2 months during which mainly subacute recurrences (whose
mechanism may differ from that of recurrences occurring later on dur-
ing follow-up) happen [11]. First detected AF was observed to be asso-
ciated with a worse short-term arrhythmia prognosis than persistent
AF, forwhichwe donot have an explanation (Table 3). Likewise, it is un-
certainwhy stable angina pectoris or absence of AF symptomswould be
associated with better rhythm outcome at 2 months.
Table 3
Factors independently associated with obtaining and maintaining sinus rhythm.
OR 95% CI P
ECVa (n= 1861)
VKA before admission 0.558 0.367–0.849 0.006
Amiodarone before admission (pretreatment) 1.557 1.04–2.33 0.03
Anesthesiologist present at CV 1.634 1.188–2.248 0.003
PCVb (n= 880)
Female gender 1.439 1.055–1.961 0.0215
AF type (Persistent AF as reference):
1st Detected AF 2.668 1.491–4.773 0.0009
Paroxysmal AF 2.216 1.269–3.870 0.0052
Previous ECV 0.531 0.319–0.883 0.0147
Heart Failure (No heart failure as reference):
NYHA I–II 0.583 0.342–0.993 0.0469
NYHA III–IV 0.400 0.144–1.111 0.0787
Valvular heart disease 0.581 0.364–0.926 0.0224
CLASS Ic PCVc(n= 272)
Female gender 2.263 1.072–4.779 0.0323
AF type (Persistent AF as reference):
1st Detected AF 3.328 1.117–9.914 0.0309
Paroxysmal AF 2.993 1.095–8.181 0.0326
Previous ECV 0.346 0.141–0.848 0.0203
Chronic renal failure 0.080 0.015–0.425 0.0030
Class III PCVd (n= 437)
AF type (persistent AF as reference):
1st detected AF 2.198 1.065–4.538 0.0332
Paroxysmal AF 1.925 0.920–4.028 0.0823
Previous ECV 0.241 0.108–0.539 0.0005
COPD 0.522 0.287–0.949 0.0330
At 2 months follow-upe (n= 2709)
Height 1.013 1.003–1.024 0.0130
Stable angina pectoris 1.438 1.029–2.008 0.0333
No AF symptoms 1.388 1.062–1.813 0.0164
AF type (persistent AF as reference)
1st detected 0.772 0.612–0.974 0.0291
Paroxysmal 0.877 0.706–1.090 0.2370
BB at admission 1.323 1.045–1.675 0.0200
AAD Use (no AAD as reference)
Continuous treatment (admission + discharge) 1.571 1.251–1.972 0.0001
Initiating treatment (discharge only) 1.240 0.995–1.547 0.0557
BP at discharge 1.398 1.107–1.765 0.0049
ACE-i/ARB at discharge 1.469 1.235–1.747 b0.0001
To maximize patients included in the multivariable analysis, for those who had missing
durations of current AF episode, median values of all paroxysmal and persistent AF pa-
tients with known duration of current AF episode were used. Patients with unknown AF
type were reclassiﬁed into paroxysmal AF if they were selected for PCV whereas all
other patients with unknown type of AF were considered to have persistent AF. AAD:
anti-arrhythmic drugs, ACE-i: ACE (angiotensin-converting-enzyme) inhibitors, ARB: an-
giotensin receptor blocker, BP: blood pressure, COPD: chronic obstructive pulmonary dis-
ease, ECV: electrical cardioversion, NYHA class: New York Heart Association functional
classiﬁcation PCV: pharmacological cardioversion, VKA: vitamin K antagonists.
594 H.J.G.M. Crijns et al. / International Journal of Cardiology 172 (2014) 588–594This study had several strengths, including its large size, the short
period of overall study time enhancing robustness of the data, the stan-
dardized collection of data, and the broad scope of patients. It was not
without limitations, including lack of full control on representativeness
of sites and on consecutiveness of patients as well as a relatively short
follow-up period. Needless to say, patients were not randomized to dif-
ferent CV types or speciﬁc drugs; apparent efﬁcacymay bemore related
to patient characteristics than to the speciﬁc drug. Therefore, a direct
comparison between different therapies is inappropriate. Nevertheless,
it offers insight into the importance of considering patient's preferences
concerning mode of CV.5. Conclusions
In current practice, pharmacological and electrical cardioversion are
safe and effective. Electrical cardioversion seems well developed, but
improvement may be obtained through pharmacological pretreatment.
Pharmacological cardioversion shortens time to conversion and if suc-
cessful, also reduces time spent in the hospital after cardioversion Ami-
odarone enhances electrical cardioversion and maintenance of sinus
rhythm, but as a conversion drug it is notmore effective than the typical
rate control drugs. Arrhythmia outcome after cardioversion is a strong
driver for admission duration and hence improvement of cardioversion
by new drugs and combination of drugs and electrical cardioversion
may reduce costs incurred by cardioversion. Finally, accounting for pa-
tients' preferences for one or the other type of cardioversion may en-
hance the medical service to patients with atrial ﬁbrillation.
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